Latest Analgesics Stories
SAN FRANCISCO, April 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate. NKTR-192 is designed to have a short-acting profile with rapid onset of pain relief for the treatment of acute pain. With a reduced rate of entry into the central nervous system (CNS) as compared to...
GLENVIEW, Ill., March 29, 2012 /PRNewswire-USNewswire/ -- Common practices for changing from one opioid to another, including use of published dose conversion ratios, may be contributing to the growing number of opioid-related fatalities, new research suggests. The results from a scientific literature review and a case study using this new model of opioid rotation are presented in the April issue of Pain Medicine, the official journal of the American Academy of Pain...
CARY, N.C., March 29, 2012 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced today that Zantac® (ranitidine hydrochloride) Injection is once again widely available for therapeutic use throughout the United States and Puerto Rico. The company launched last year as a distributor for a product portfolio that addresses life threatening and other serious medical conditions in the cardiovascular, central nervous system and acute care markets. "Covis was formed to reliably provide...
Orange County Rehab 449Recovery speaks out against opiate addiction. San Clemente, CA (PRWEB) March 28, 2012 According to a story released on the New England Cable News website, the state of Oklahoma is now the number one state in prescription pain pill addiction and abuse. What is more disturbing according to data within the article is that the number of deaths as a result of drug overdoses is now averaging two a day; which is higher than the number of deaths caused annually by...
Researchers report no significant difference in high versus low dose aspirin in preventing recurring cardiovascular events. Each year, more than one million Americans suffer a heart attack and nearly all patients are prescribed a daily aspirin and an antiplatelet medication during recovery. However, the optimal aspirin dose has been unclear. Now, new research from Brigham and Women's Hospital (BWH) reports that there is no significant difference between high versus low dose aspirin in...
Dealing with Rising Rates of Oxycodone Abuse New York, NY (PRWEB) March 23, 2012 New York physician Dr. Marina Gafanovich, MD has long advised that the abuse of the drug Oxycodone (OxyContin) would become not only a major medical issue among chronic pain users, as more and more legislation is being passed to narrow the prescriptive use of this drug, but also would drive the rates of drug crimes sky high as these medicinal use patients found themselves without this powerful drug for the...
Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to a perspective paper published online ahead of print publication by the International Journal of Clinical Practice. American doctors Leslie Citrome and Amy Weiss-Citrome analysed the latest clinical evidence on duloxetine, a well-established antidepressant that received...
On March 12th 2012, BioDelivery Sciences International, Inc. announced that the U.S. re-launch of Onsolis (Fentanyl buccal soluble film) is being postponed until the product formulation can be modified to address two appearance issues raised by the U.S. Food and Drug Administration (FDA). Fentanyl (brand names Duragesic, Onsolis and others) is a potent synthetic narcotic analgesic used to treat breakthrough cancer pain and is commonly used in pre-procedures as a pain reliever as well as an...
RALEIGH, N.C., March 19, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2011, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of the Company's achievements and an update on business operations and upcoming milestones for 2012. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) In 2011, BDSI...
